Clinical trials: Pneumonia - Bacterial
Staphylococcus Aureus Pneumonia
Study of the Efficacy and Safety of MEDI4893
Clinical trial looking at safety and efficacy of MEDI4893 in prevention of pneumonia caused by Staphylococcus aureus in high-risk patients
- Trial name
- SAATELLITE (NCT02296320)
- Testing
- MEDI4893
- Where
- 49 sites in United States, Belgium and 8 more
- Volunteers
- 213 people
- Sponsor
- MedImmune LLC
Influenza, SARS (Severe Acute Respiratory Syndrome)
Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)
Respiratory infections such as colds, flu and pneumonia affect millions of people around the world every year. Most cases are mild, but some people become very unwell.
- Conditions
- Influenza, SARS (Severe Acute Respiratory Syndrome), Respiratory Viral Infection, Respiratory Tract Infections
- Trial name
- PREDICT-ILI (NCT04664075)
- Testing
- Respiratory infections
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Imperial College London
Pneumococcal Infections, Pneumonia, Pneumococcal
Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)
The primary objectives are to evaluate the safety and tolerability of V114 and to compare the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) across 3 different lots of V114.
- Trial name
- PNEU-TRUE (NCT03950856)
- Testing
- V114, Prevnar 13™
- Where
- 55 sites in United States, Australia and 4 more
- Volunteers
- 2,340 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumonia, Pneumococcal
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)
This a study of V116 in adults ≥50 years of age who concomitantly received Influenza vaccine. The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of V116 when administered…
- Trial name
- NCT05526716
- Testing
- V116, QIV
- Where
- 56 sites in United States
- Volunteers
- 1,080 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pneumonia, Bacterial
Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia
To demonstrate that as adjunctive therapy to intravenous (IV) antibiotics, BAY 41-6551 400 mg (amikacin as free base) administered as an aerosol by the Pulmonary Drug Delivery System (PDDS) Clinical every 12 hours is safe and…
- Trial name
- INHALE 1 (NCT01799993)
- Testing
- Amikacin Inhalation Solution (BAY41-6551)
- Where
- 65 sites in United States, Australia and 10 more
- Volunteers
- 725 people
- Sponsor
- Bayer
Cystic Fibrosis, Pneumonia
Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
This study will determine the concentrations of the antibiotic meropenem when administered as a 3 hour prolonged infusion in children with cystic fibrosis who are hospitalized with an acute pulmonary exacerbation.
- Conditions
- Cystic Fibrosis, Pneumonia, Pseudomonas Aeruginosa Infection
- Trial name
- NCT01429259
- Testing
- meropenem
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Joseph Kuti
Covid19, Tuberculosis
New Reusable Mask Design With Superior Filtration and Fit
This study will test the filtration, air leak, and breathability of a newly designed fully washable mask developed by Dr. Nordell with the Mayo Clinic.
- Conditions
- Covid19, Tuberculosis, Respiratory Viral Infection
- Trial name
- NCT04826809
- Testing
- N95 mask, Nordell single E-100 layer mask, Nordell double E-100 layer mask
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Gram-negative Bacterial Infections, Bloodstream Infections (BSI)
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants
The primary objectives of this study are: To assess the safety and tolerability of cefiderocol after single-dose administration in hospitalized paediatric participants 3 months to < 18 years of age with suspected or confirmed…
- Conditions
- Gram-negative Bacterial Infections, Bloodstream Infections (BSI), Complicated Intra-abdominal Infection (cIAI), Hospital Acquired Pneumonia (HAP)
- Trial name
- NCT04335539
- Testing
- Cefiderocol, Standard of Care
- Where
- 23 sites in Belgium, Estonia and 7 more
- Volunteers
- 53 people
- Sponsor
- Shionogi
Infectious Disease, Pneumonia, Bacterial
Vaccination Education Through Pharmacists and Senior Centers (VEPSC)
The study consists of two arms (PHARM and PEER) designed to educate participants about three vaccine-preventable diseases (zoster, pneumonia, and influenza) and vaccination.
- Conditions
- Infectious Disease, Pneumonia, Bacterial, Influenza, Zoster; Herpes
- Trial name
- VEPSC (NCT03239665)
- Testing
- Pharmacist-led Intervention (PHARM), Peer-led Intervention (PEER)
- Where
- United States
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b
Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children
Evaluate the persistency of immune response against Haemophilus influenzae type b by assessing anti-PRP antibody levels in children vaccinated with either Hib-CRM197 or Hib-TT booster vaccine approximately 4 years before.
- Trial name
- NCT02139228
- Testing
- Hib-CRM197, Hib-TT
- Where
- China
- Volunteers
- 426 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Coccidioidomycosis
Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment
The purpose of this study is to determine if nikkomycin Z is safe when administered at different dose levels for 14 days. The study will also determine blood levels and urinary excretion of nikkomycin Z in relation to dose…
- Trial name
- NCT00614666
- Testing
- nikkomycin Z
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Arizona
Nosocomial Infections, Pneumonia, Ventilator-Associated
A Efficacy and Safety Study of Nasal Prongs With Proprietary Surface Coating Aiming to Reduce Bacterial Colonization
The study is a first step in establishing the safety and efficacy of the CytaCoat technology when applied to a medical device such as a nasal prong and the clinical data generated will serve as a basis for continuous studies in…
- Trial name
- NCT02756351
- Testing
- CytaCoat Nasal Prong, Inspiration Healthcare Inspire nCPAP Nasal Prong
- Where
- Sweden
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- CytaCoat AB
Pneumonia, Bacterial, Healthy Volunteers
A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of 3 different dose levels of ASP3772 in comparison to the active comparator Prevnar 13® (PCV13) in adults 18 to 64 years of age in Stage 1.
- Conditions
- Pneumonia, Bacterial, Healthy Volunteers, Pneumococcal Disease
- Trial name
- NCT03803202
- Testing
- ASP3772, PCV13, PPSV23
- Where
- 26 sites in United States
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bacterial Pneumonia
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
Study 0015 (NCT00107952) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
- Trial name
- ATTAIN1 (NCT00107952)
- Testing
- Telavancin, Vancomycin
- Where
- United States
- Volunteers
- 761 people
- Sponsor
- Cumberland Pharmaceuticals
Cystic Fibrosis
A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations
This study investigates the use of cysteamine in the treatment of adults with Cystic Fibrosis who are experiencing an exacerbation of CF-associated lung disease.
- Trial name
- CARE-CF1 (NCT03000348)
- Testing
- Cysteamine
- Where
- 17 sites in United States, Italy and 1 more
- Volunteers
- 91 people
- Sponsor
- NovaBiotics Ltd.
Bacterial Pneumonia, Community-Acquired Infections
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.
- Trial name
- NCT02531438
- Testing
- Omadacycline, Moxifloxacin
- Where
- 140 sites in United States, Belgium and 23 more
- Volunteers
- 774 people
- Sponsor
- Paratek Pharmaceuticals Inc
Community-acquired Pneumonia
Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia
The purpose of this study is to evaluate the pharmacokinetics of an oral omadacycline dosing regimen in the treatment of adults with CABP.
- Trial name
- NCT04160260
- Testing
- Omadacycline
- Where
- 13 sites in United States
- Volunteers
- 18 people
- Sponsor
- Paratek Pharmaceuticals Inc
Community Acquired Pneumonia
Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine
The aim of this study is to test if BPS (Bacterial Pneumonia Score) guided antibiotic use in children with non severe community acquired pneumonia (CAP) and pneumoccocal vaccine will reduce antibiotic use as compared to standard…
- Trial name
- NCT01875731
- Testing
- BPS, Guideline
- Where
- Argentina
- Volunteers
- 66 people
- Sponsor
- Hospital General de Niños Pedro de Elizalde
Pneumococcal Pneumonia, Influenza
The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine
The immunogenicity of simultaneous administration of quadrivalent influenza vaccine and pneumococcal vaccine was unknown. The purpose of present study is to compare the immunogenicity of simultaneous administration of influenza…
- Trial name
- NCT02592486
- Testing
- Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®, Sequential administration of Pneumovax NP® and Fluvic HA syringe®
- Where
- Japan
- Volunteers
- 162 people
- Sponsor
- Kameda Medical Center
Pneumonia, Pneumococcal
Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants
The primary objectives of this study are to evaluate the immunogenicity (antibody response) and safety and tolerability of a 2-dose primary series and booster dose (2+1 schedule) of Pneumosil co-administered with routine…
- Trial name
- NCT03896477
- Testing
- Pneumosil, Prevenar 13, Synflorix
- Where
- The Gambia
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- PATH